Fate’s IND Application for CAR T Cell Therapy Gets FDA Nod – Zacks.com

Clinical-stage biopharmaceutical company, Fate Therapeutics, Inc. (FATE - Free Report) , announced that the FDA has cleared its Investigational New Drug (IND) application for pipeline candidate, FT819.

FT819 is an off-the-shelf allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. It has been derived from a clonal master induced pluripotent stem cell (iPSC) line.

Fate plans to initiate a study on FT819 for the treatment of patients with relapsed/refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL).

The multi-center phase I study of FT819 will determine the maximum tolerated dose of FT819. The study will assess its safety and clinical activity in up to 297 adult patients across these three types of B-cell malignancies.

The company will enroll independently for each indication. The candidate will be evaluated in three dose-escalating treatment regimens Regimen A as a single dose of FT819, Regimen B as a single dose of FT819 with IL-2 cytokine support and Regimen C as three fractionated doses of FT819. Additionally, dose-expansion cohorts of up to 15 patients may be enrolled to further evaluate the clinical activity of FT819 for each indication and regimen.

We note that Fates immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and target tumor-associated antigens with CARs. The immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a phase II study for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders.

To develop its pipeline, Fate has entered into collaborations with other companies.

The company has entered into a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates.

In April 2020, Fate entered into a collaboration and option agreement with Janssen Biotech, Inc., a unit of Johnson & Johnson (JNJ - Free Report) , to develop iPSC-derived CAR NK and CAR T-cell product candidates for the treatment of cancer. Shares surged on the collaboration news.

The companys shares have soared 85.8% so far this year compared with the industrys growth of 12.3%

Cellular immunotherapies promise huge potential. Hence, companies like Gilead Sciences, Inc. (GILD - Free Report) and Bristol-Myers Squibb Company (BMY - Free Report) are currently focusing on the development of cellular immunotherapies for the treatment of cancer.

Fate currently carries a Zacks Rank #3 (Hold). You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here.

These Stocks Are Poised to Soar Past the Pandemic

The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.

Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for stay at home technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.

See the 5 high-tech stocks now>>

See more here:
Fate's IND Application for CAR T Cell Therapy Gets FDA Nod - Zacks.com

New Report: Leukemia Cancer Market Share, Growth, Trend Analysis and Forecast from 2020-2026; Consumption Capacity by Volume and Production Value|…

LOS ANGELES, United States: QY Research has recently published a report, titled Global Leukemia Cancer Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Leukemia Cancer market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Leukemia Cancer market include: Biogen, GSK, Novartis, Pfizer, Roche, Takeda Oncology, Teva Pharmaceutical, Celgene, Daiichi Sankyo, EISAI, Sunesis Pharmaceuticals, Bristol-Myers Squibb, Spectrum Pharmaceuticals

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1605813/global-leukemia-cancer-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Leukemia Cancer market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Leukemia Cancer Market Segment By Type:

Chemotherapy Radiation Therapy Targeted Therapy Biological Therapy Stem Cell Transplant

Global Leukemia Cancer Market Segment By Application:

Acute Myeloid Leukaemia (AML) Chronic Myeloid Leukaemia (CML) Acute Lymphoblastic Leukaemia (ALL) Chronic Lymphocytic Leukaemia (CLL) Global Leukemia Cancer

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Leukemia Cancer market.

Key companies operating in the global Leukemia Cancer market include Biogen, GSK, Novartis, Pfizer, Roche, Takeda Oncology, Teva Pharmaceutical, Celgene, Daiichi Sankyo, EISAI, Sunesis Pharmaceuticals, Bristol-Myers Squibb, Spectrum Pharmaceuticals

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1605813/global-leukemia-cancer-market

TOC

1 Market Overview of Leukemia Cancer 1.1 Leukemia Cancer Market Overview 1.1.1 Leukemia Cancer Product Scope 1.1.2 Market Status and Outlook 1.2 Global Leukemia Cancer Market Size Overview by Region 2015 VS 2020 VS 2026 1.3 Global Leukemia Cancer Market Size by Region (2015-2026) 1.4 Global Leukemia Cancer Historic Market Size by Region (2015-2020) 1.5 Global Leukemia Cancer Market Size Forecast by Region (2021-2026) 1.6 Key Regions, Leukemia Cancer Market Size YoY Growth (2015-2026) 1.6.1 North America Leukemia Cancer Market Size YoY Growth (2015-2026) 1.6.2 Europe Leukemia Cancer Market Size YoY Growth (2015-2026) 1.6.3 Asia-Pacific Leukemia Cancer Market Size YoY Growth (2015-2026) 1.6.4 Latin America Leukemia Cancer Market Size YoY Growth (2015-2026) 1.6.5 Middle East & Africa Leukemia Cancer Market Size YoY Growth (2015-2026) 2 Leukemia Cancer Market Overview by Type 2.1 Global Leukemia Cancer Market Size by Type: 2015 VS 2020 VS 2026 2.2 Global Leukemia Cancer Historic Market Size by Type (2015-2020) 2.3 Global Leukemia Cancer Forecasted Market Size by Type (2021-2026) 2.4 Chemotherapy 2.5 Radiation Therapy 2.6 Targeted Therapy 2.7 Biological Therapy 2.8 Stem Cell Transplant 3 Leukemia Cancer Market Overview by Application 3.1 Global Leukemia Cancer Market Size by Application: 2015 VS 2020 VS 2026 3.2 Global Leukemia Cancer Historic Market Size by Application (2015-2020) 3.3 Global Leukemia Cancer Forecasted Market Size by Application (2021-2026) 3.4 Acute Myeloid Leukaemia (AML) 3.5 Chronic Myeloid Leukaemia (CML) 3.6 Acute Lymphoblastic Leukaemia (ALL) 3.7 Chronic Lymphocytic Leukaemia (CLL) 4 Global Leukemia Cancer Competition Analysis by Players 4.1 Global Leukemia Cancer Market Size (Million US$) by Players (2015-2020) 4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Leukemia Cancer as of 2019) 4.3 Date of Key Manufacturers Enter into Leukemia Cancer Market 4.4 Global Top Players Leukemia Cancer Headquarters and Area Served 4.5 Key Players Leukemia Cancer Product Solution and Service 4.6 Competitive Status 4.6.1 Leukemia Cancer Market Concentration Rate 4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data 5.1 Biogen 5.1.1 Biogen Profile 5.1.2 Biogen Main Business 5.1.3 Biogen Products, Services and Solutions 5.1.4 Biogen Revenue (US$ Million) & (2015-2020) 5.1.5 Biogen Recent Developments 5.2 GSK 5.2.1 GSK Profile 5.2.2 GSK Main Business and Companys Total Revenue 5.2.3 GSK Products, Services and Solutions 5.2.4 GSK Revenue (US$ Million) (2015-2020) 5.2.5 GSK Recent Development and Reaction to Covid-19 5.3 Novartis 5.5.1 Novartis Profile 5.3.2 Novartis Main Business 5.3.3 Novartis Products, Services and Solutions 5.3.4 Novartis Revenue (US$ Million) & (2015-2020) 5.3.5 Pfizer Recent Developments 5.4 Pfizer 5.4.1 Pfizer Profile 5.4.2 Pfizer Main Business 5.4.3 Pfizer Products, Services and Solutions 5.4.4 Pfizer Revenue (US$ Million) & (2015-2020) 5.4.5 Pfizer Recent Developments 5.5 Roche 5.5.1 Roche Profile 5.5.2 Roche Main Business 5.5.3 Roche Products, Services and Solutions 5.5.4 Roche Revenue (US$ Million) & (2015-2020) 5.5.5 Roche Recent Developments 5.6 Takeda Oncology 5.6.1 Takeda Oncology Profile 5.6.2 Takeda Oncology Main Business 5.6.3 Takeda Oncology Products, Services and Solutions 5.6.4 Takeda Oncology Revenue (US$ Million) & (2015-2020) 5.6.5 Takeda Oncology Recent Developments 5.7 Teva Pharmaceutical 5.7.1 Teva Pharmaceutical Profile 5.7.2 Teva Pharmaceutical Main Business and Companys Total Revenue 5.7.3 Teva Pharmaceutical Products, Services and Solutions 5.7.4 Teva Pharmaceutical Revenue (US$ Million) (2015-2020) 5.7.5 Teva Pharmaceutical Recent Development and Reaction to Covid-19 5.8 Celgene 5.8.1 Celgene Profile 5.8.2 Celgene Main Business 5.8.3 Celgene Products, Services and Solutions 5.8.4 Celgene Revenue (US$ Million) & (2015-2020) 5.8.5 Celgene Recent Developments 5.9 Daiichi Sankyo 5.9.1 Daiichi Sankyo Profile 5.9.2 Daiichi Sankyo Main Business 5.9.3 Daiichi Sankyo Products, Services and Solutions 5.9.4 Daiichi Sankyo Revenue (US$ Million) & (2015-2020) 5.9.5 Daiichi Sankyo Recent Developments 5.10 EISAI 5.10.1 EISAI Profile 5.10.2 EISAI Main Business 5.10.3 EISAI Products, Services and Solutions 5.10.4 EISAI Revenue (US$ Million) & (2015-2020) 5.10.5 EISAI Recent Developments 5.11 Sunesis Pharmaceuticals 5.11.1 Sunesis Pharmaceuticals Profile 5.11.2 Sunesis Pharmaceuticals Main Business 5.11.3 Sunesis Pharmaceuticals Products, Services and Solutions 5.11.4 Sunesis Pharmaceuticals Revenue (US$ Million) & (2015-2020) 5.11.5 Sunesis Pharmaceuticals Recent Developments 5.12 Bristol-Myers Squibb 5.12.1 Bristol-Myers Squibb Profile 5.12.2 Bristol-Myers Squibb Main Business 5.12.3 Bristol-Myers Squibb Products, Services and Solutions 5.12.4 Bristol-Myers Squibb Revenue (US$ Million) & (2015-2020) 5.12.5 Bristol-Myers Squibb Recent Developments 5.13 Spectrum Pharmaceuticals 5.13.1 Spectrum Pharmaceuticals Profile 5.13.2 Spectrum Pharmaceuticals Main Business 5.13.3 Spectrum Pharmaceuticals Products, Services and Solutions 5.13.4 Spectrum Pharmaceuticals Revenue (US$ Million) & (2015-2020) 5.13.5 Spectrum Pharmaceuticals Recent Developments 6 North America 6.1 North America Leukemia Cancer Market Size by Country 6.2 United States 6.3 Canada 7 Europe 7.1 Europe Leukemia Cancer Market Size by Country 7.2 Germany 7.3 France 7.4 U.K. 7.5 Italy 7.6 Russia 7.7 Nordic 7.8 Rest of Europe 8 Asia-Pacific 8.1 Asia-Pacific Leukemia Cancer Market Size by Region 8.2 China 8.3 Japan 8.4 South Korea 8.5 Southeast Asia 8.6 India 8.7 Australia 8.8 Rest of Asia-Pacific 9 Latin America 9.1 Latin America Leukemia Cancer Market Size by Country 9.2 Mexico 9.3 Brazil 9.4 Rest of Latin America 10 Middle East & Africa 10.1 Middle East & Africa Leukemia Cancer Market Size by Country 10.2 Turkey 10.3 Saudi Arabia 10.4 UAE 10.5 Rest of Middle East & Africa 11 Leukemia Cancer Market Dynamics 11.1 Industry Trends 11.2 Market Drivers 11.3 Market Challenges 11.4 Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach 13.1.1 Research Programs/Design 13.1.2 Market Size Estimation 13.1.3 Market Breakdown and Data Triangulation 13.2 Data Source 13.2.1 Secondary Sources 13.2.2 Primary Sources 13.3 Disclaimer 13.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See the article here:
New Report: Leukemia Cancer Market Share, Growth, Trend Analysis and Forecast from 2020-2026; Consumption Capacity by Volume and Production Value|...

Blood and Bone Marrow Cancer Treatment Growth to be Fuelled by 2019-2025 – 3rd Watch News

This report presents the worldwide Blood and Bone Marrow Cancer Treatment market size (value, production and consumption), splits the breakdown (data status 2019 and forecast to 2025), by manufacturers, region, type and application.

This study also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porters Five Forces Analysis.

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2705147&source=atm

The report provides a valuable source of insightful data for business strategists and competitive analysis of Blood and Bone Marrow Cancer Treatment Market. It provides the Blood and Bone Marrow Cancer Treatment industry overview with growth analysis and futuristic cost, revenue and many other aspects. The research analysts provide an elaborate description of the value chain and its distributor analysis. This Tire Blood and Bone Marrow Cancer Treatment study provides comprehensive data which enhances the understanding, scope and application of this report.

segment by Type, the product can be split into Chemotherapy Immunotherapy Stem Cell Transplant Radiotherapy Market segment by Application, split into Multiple Myeloma Leukemia Lymphoma Others

Market segment by Regions/Countries, this report covers North America Europe China Japan Southeast Asia India Central & South America

The study objectives of this report are: To analyze global Blood and Bone Marrow Cancer Treatment status, future forecast, growth opportunity, key market and key players. To present the Blood and Bone Marrow Cancer Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America. To strategically profile the key players and comprehensively analyze their development plan and strategies. To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Blood and Bone Marrow Cancer Treatment are as follows: History Year: 2015-2019 Base Year: 2019 Estimated Year: 2020 Forecast Year 2020 to 2026 For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2705147&source=atm

Regional Analysis For Blood and Bone Marrow Cancer Treatment Market:

For comprehensive understanding of market dynamics, the global Blood and Bone Marrow Cancer Treatment market is analyzed across key geographies namely: United States, China, Europe, Japan, South-east Asia, India and others. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Influence of the Blood and Bone Marrow Cancer Treatment market report:

-Comprehensive assessment of all opportunities and risk in the Blood and Bone Marrow Cancer Treatment market.

Blood and Bone Marrow Cancer Treatment market recent innovations and major events.

-Detailed study of business strategies for growth of the Blood and Bone Marrow Cancer Treatment market-leading players.

-Conclusive study about the growth plot of Blood and Bone Marrow Cancer Treatment market for forthcoming years.

-In-depth understanding of Blood and Bone Marrow Cancer Treatment market-particular drivers, constraints and major micro markets.

-Favorable impression inside vital technological and market latest trends striking the Blood and Bone Marrow Cancer Treatment market.

The report has 150 tables and figures browse the report description and TOC:

Table of Contents of Blood and Bone Marrow Cancer Treatment Market

1 Study Coverage

1.1 Blood and Bone Marrow Cancer Treatment Product

1.2 Key Market Segments in This Study

1.3 Key Manufacturers Covered

1.4 Market by Type

1.4.1 Global Blood and Bone Marrow Cancer Treatment Market Size Growth Rate by Type

1.4.2 Hydraulic Dredges

1.4.3 Hopper Dredges

1.4.4 Mechanical Dredges

1.5 Market by Application

1.5.1 Global Blood and Bone Marrow Cancer Treatment Market Size Growth Rate by Application

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2705147&licType=S&source=atm

2 Executive Summary

2.1 Global Blood and Bone Marrow Cancer Treatment Market Size

2.1.1 Global Blood and Bone Marrow Cancer Treatment Revenue 2014-2025

2.1.2 Global Blood and Bone Marrow Cancer Treatment Production 2014-2025

2.2 Blood and Bone Marrow Cancer Treatment Growth Rate (CAGR) 2019-2025

2.3 Analysis of Competitive Landscape

2.3.1 Manufacturers Market Concentration Ratio (CR5 and HHI)

2.3.2 Key Blood and Bone Marrow Cancer Treatment Manufacturers

2.3.2.1 Blood and Bone Marrow Cancer Treatment Manufacturing Base Distribution, Headquarters

2.3.2.2 Manufacturers Blood and Bone Marrow Cancer Treatment Product Offered

2.3.2.3 Date of Manufacturers Enter into Blood and Bone Marrow Cancer Treatment Market

2.4 Key Trends for Blood and Bone Marrow Cancer Treatment Markets & Products

3 Market Size by Manufacturers

3.1 Blood and Bone Marrow Cancer Treatment Production by Manufacturers

3.1.1 Blood and Bone Marrow Cancer Treatment Production by Manufacturers

3.1.2 Blood and Bone Marrow Cancer Treatment Production Market Share by Manufacturers

3.2 Blood and Bone Marrow Cancer Treatment Revenue by Manufacturers

3.2.1 Blood and Bone Marrow Cancer Treatment Revenue by Manufacturers (2019-2025)

3.2.2 Blood and Bone Marrow Cancer Treatment Revenue Share by Manufacturers (2019-2025)

3.3 Blood and Bone Marrow Cancer Treatment Price by Manufacturers

3.4 Mergers & Acquisitions, Expansion Plans

More Information.

Continued here:
Blood and Bone Marrow Cancer Treatment Growth to be Fuelled by 2019-2025 - 3rd Watch News

Stem Cell Therapy Market Growth By Manufacturers, Countries, Types And Application, End Users And Forecast To 2026 – 3rd Watch News

Allosource

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Industrial Analysis:

The Stem Cell Therapy market report is extensively categorized into different product types and applications. The study has a separate section for explaining the cost of raw material and the revenue returns that are gained by the players of the market.

The segmentation included in the report is beneficial for readers to capitalize on the selection of appropriate segments for the Stem Cell Therapy sector and can help companies in deciphering the optimum business move to reach their desired business goals.

In Market Segmentation by Types of Stem Cell Therapy, the report covers-

Bytype1

In Market Segmentation by Applications of the Stem Cell Therapy, the report covers the following uses-

Byapplication1

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=3WN&utm_medium=003

The Stem Cell Therapy market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Stem Cell Therapy market.

This study analyzes the growth of Stem Cell Therapy based on the present, past and futuristic data and will render complete information about the Stem Cell Therapy industry to the market-leading industry players that will guide the direction of the Stem Cell Therapy market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Stem Cell Therapy market. Additionally, it includes a share of each segment of the Stem Cell Therapy market, giving methodical information about types and applications of the market.

Reasons for Buying Stem Cell Therapy Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Stem Cell Therapy market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=3WN&utm_medium=003

In the end, the Stem Cell Therapy market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the Stem Cell Therapy market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080 UK: +44 (203)-411-9686 APAC: +91 (902)-863-5784 US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

See the rest here:
Stem Cell Therapy Market Growth By Manufacturers, Countries, Types And Application, End Users And Forecast To 2026 - 3rd Watch News

Canine arthritis treatment market will Record a Sluggish 4.0% CAGR through (2019-2029) – 3rd Watch News

Canine Arthritis Treatment Analysis 2019-2029

A recent market study published by Future Market Insights (FMI) on the canine arthritis treatment including global industry analysis 2014-2018 & opportunity assessment 2019-2029, delivers a comprehensive assessment of the most important market dynamics. After conducting a thorough research on the historical as well as current growth parameters of thecanine arthritis treatment market, the growth prospects of the market are obtained with maximum precision.

The global canine arthritis treatment is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Chapter 01 Executive Summary

The report initiates with the executive summary of the canine arthritis treatment, which includes a summary of key findings and statistics of the market. It also includes market size and revenue distribution of market segment of the canine arthritis treatment.

To Get the Sample Copy of Report visit @https://www.futuremarketinsights.com/reports/sample/rep-gb-3552

Chapter 02 Market Overview

Readers can find the definition and a detailed segmentation of the canine arthritis treatment in this chapter, which will help them understand the basic information about the canine arthritis treatment.

Chapter 03 Market Background

This chapter explains the key macroeconomic factors, drivers, restraints, trends and opportunity analysis that are expected to influence the growth of the canine arthritis treatment over the forecast period. Moreover, in-depth information about the market dynamics and their impact analysis on the market have been provided in the successive section.

Chapter 04 Market Context

This section includes premium insights such as regulatory scenario, disease epidemiology, industry view point and market evolution. This section helps readers understand the key factors associated with the canine arthritis treatment market.

Chapter 05 Global Canine Arthritis Treatment Value Analysis 2014-2018 & Opportunity Assessment 2019-2029

This section explains the global market value analysis and forecast for the Canine Arthritis treatment between the forecast periods of 2019-2029. This chapter includes a detailed analysis of the historical canine arthritis treatment market, along with an opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2019), and an incremental $ opportunity for the forecast period (20192029).

Chapter 06 Global Canine Arthritis Treatment Analysis 2014-2018 & Opportunity Assessment 2019-2029, by Treatment

Based on treatment type, the canine arthritis treatment market is segmented into Non-steroidal anti-inflammatory medications (NSAIDs), opioids and stem cell therapy. In this chapter, readers can find information about the key trends and developments in the canine arthritis treatment and market attractiveness analysis based on treatment.

Chapter 07 Global Canine Arthritis Treatment Analysis 2014-2018 & Opportunity Assessment 2019-2029, by Route of Administration

This chapter provides details about the canine arthritis treatment based on mode of administration, and has been classified into oral and injectable. In this chapter, readers can understand the market attractiveness analysis based on route of administration.

Chapter 08 Global Canine Arthritis Treatment Analysis 2014-2018 & Opportunity Assessment 2019-2029, by Distribution Channel

This chapter provides details about the canine arthritis treatment market based on distribution channel, and has been classified into veterinary hospitals and clinics, retail pharmacies, drug stores, and E-Commerce. In this chapter, readers can understand the market attractiveness analysis based on distribution channel.

Chapter 09 Global Canine Arthritis Treatment Analysis 2014-2018 & Opportunity Assessment 2019-2029, by Region

This chapter explains how the canine arthritis treatment market will grow across various geographic regions such as North America, Latin America, Europe, Asia-Pacific excluding Japan, Japan, and Middle East & Africa (MEA).

Chapter 10 North America Canine Arthritis Treatment Analysis 2014-2018 & Opportunity Assessment 2019-2029

This chapter includes a detailed analysis of the growth of the North America canine arthritis treatment market, along with a country-wise assessment that includes the U.S. and Canada. Readers can also find the pricing analysis, regional trends, and market growth based on the application and countries in North America.

Download Methodology of this Report @https://www.futuremarketinsights.com/askus/rep-gb-3552

Chapter 11 Latin America Canine Arthritis Treatment Analysis 2014-2018 & Opportunity Assessment 2019-2029

This chapter provides the growth scenario of the canine arthritis treatment market in Latin American countries such as Brazil, Mexico, and the Rest of Latin America. Along with this, assessment of the market across target segments has been provided.

Chapter 12 Europe Canine Arthritis Treatment Analysis 2014-2018 & Opportunity Assessment 2019-2029

Important growth prospects of the canine arthritis treatment market based on its Distribution Channels in several countries such as Germany, the U.K., France, Spain, Italy, Russia, and the Rest of Europe are included in this chapter.

Chapter 13 Asia Pacific Excluding Japan Canine Arthritis Treatment Analysis 2014-2018 & Opportunity Assessment 2019-2029

This chapter highlights the growth of the canine arthritis treatment in Asia pacific excluding Japan by focusing on China, India, Australia & New Zealand, ASEAN and rest of APEJ. This section also help readers understand the key factors that are responsible for the growth of the canine arthritis treatment market in the APEJ region.

Chapter 14 Japan Canine Arthritis Treatment Analysis 2014-2018 & Opportunity Assessment 2019-2029

This chapter highlights the growth of the canine arthritis treatment in Japan. This section also help readers understand the key factors that are responsible for the growth of the canine arthritis treatment market in Japan.

Chapter 15 MEA Canine Arthritis Treatment Analysis 2014-2018 & Opportunity Assessment 2019-2029

This chapter provides information about how the canine arthritis treatment market will grow in major countries in the MEA region such as GCC Countries, South Africa, and the Rest of MEA, during the forecast period of 2019-2029.

Chapter 16 Competition Analysis

In this chapter, readers can find a comprehensive list of all the prominent stakeholders in the canine arthritis treatment market, along with a detailed information about each company, which includes company overview, revenue shares, strategic overview, and recent company developments. Some of the market players featured in the report are Elanco, Zoetis, Bayer, VetStem Biopharma and among others.

Chapter 17 Assumptions and Acronyms

This chapter includes a list of acronyms and assumptions that provides a base to the information and statistics included in the canine arthritis treatment report.

Chapter 18 Research Methodology

This chapter help readers understand the research methodology followed to obtain various conclusions as well as important qualitative and quantitative information about The Canine Arthritis Treatment.

Request for covid19 impact Analysis @https://www.futuremarketinsights.com/covid19/rep-gb-3552

Sources and Primary Research Splits (%)

Industry Interactions

References Catalogue

View original post here:
Canine arthritis treatment market will Record a Sluggish 4.0% CAGR through (2019-2029) - 3rd Watch News

Global Autologous Cell Therapy Market Revenue Outcome, Robust Vendors, and Investment Prospects – 3rd Watch News

Market Research Exploreoffers an exhaustive analysis on the Global Autologous Cell Therapy Market covering diverse significant factors that pose an impact on the current and forthcoming market conditions. The report elaborates on how the Autologous Cell Therapy market has been performing over the last five years at the global and regional levels. It also analyzes expected ups and downs in the market over the next five years. The report assists market players to operate their business wisely. Market scope, establishment, profitability, maturity, and growth prospects are also highlighted in the global Autologous Cell Therapy market report.

The report mainly emphasizes the market rivalry landscape, leading players profiles, segmentation, and industry environments which have been playing an integral role in posing impacts on market structure and profitability. It also includes a precise assessment of market share, size, demand, production, sales, and revenue that help intuit the financial health of the industry. It also illuminates various market dynamics such as changing product values, demand-supply variations, contemporary trends, pricing fluctuations, growth-driving forces, and unstable market conditions.

Sample Copy Global Autologous Cell Therapy Market Report 2020:https://www.marketresearchexplore.com/report/global-autologous-cell-therapy-industry-market-research-report/174131#enquiry

Extensive study of crucial Autologous Cell Therapy market segments:

The global Autologous Cell Therapy market has been segmented into a number of various vital segments such as types, applications, and regions. The report evaluates each segment at a minute level in view of its growth prospects, global demand, and current revenue. It also focuses on the segments that are exhibiting exponential growth during the year and help market players in selecting more profitable segments for their Autologous Cell Therapy businesses and precisely determine the actual needs and wants of their customer base.

Global Autologous Cell Therapy Market Competitive Assessment:

Expansive survey of Global Autologous Cell Therapy Market 2020

According to the report findings, the global Autologous Cell Therapy market report is extremely competitive and encouraging leading manufacturers and companies to execute various business and marketing strategies such as M&A activities, brand promotions, product launches, partnerships, and other expansions to perform comfortably in the relentless competition. The report further examines highlights new product developments, innovations, and technology adoptions done by the competitors in order to offer upgraded products and services in the global Autologous Cell Therapy market.

The report also provides a detailed financial assessment of leading market vendors and insights into the competencies and capacities of these companies to assist Autologous Cell Therapy market players for business expansions. The report also deeply analyzes effective product lines offered by various manufacturers and helps other participants to boost the quality of their products. Analysis based on forthcoming challenges and opportunities is also highlighted in the report, which will help Autologous Cell Therapy market players build lucrative strategies and grab all growth opportunities.

Significant Features of the Global Autologous Cell Therapy Market Report:

Connect with our industry experts at[emailprotected].

View post:
Global Autologous Cell Therapy Market Revenue Outcome, Robust Vendors, and Investment Prospects - 3rd Watch News

Hemostemix Files Its Audited Annual Financial Statements and Management Discussion and Analysis for the Period Ending December 31, 2019 – Yahoo…

Calgary, Alberta--(Newsfile Corp. - July 10, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") today filed on SEDAR its audited Financial Statements and Management Discussion and Analysis for the annual period and fourth quarter ending December 31, 2019 and for the comparable periods ending December 31, 2018.

ABOUT HEMOSTEMIX

Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup" which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, please visit http://www.hemostemix.com.

Contact: Thomas Smeenk, President, CEO & Co-Founder TSmeenk@Hemostemix.com 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the commercialization of ACP-01. There can be no assurances that such forward-looking information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix which the Company believes are reasonable. These assumptions include, but are not limited to: the results of ACP-01 research, trials and studies being equivalent to or better than previous research, trials or studies as well as management's expectations of anticipated results; Hemostemix's general and administrative costs remaining constant; the receipt of all required regulatory approvals for research, trials or studies as well as any required or desired financings of Hemostemix, including TSX Venture Exchange acceptance and any third party consents; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete its current CLI clinical trial, complete a satisfactory futility analysis and the results of such and future clinical trials; litigation and potential litigation that Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in the Company's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, economic activity financing, supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession; the potential impact that the COVID-19 pandemic may have on Hemostemix may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at http://www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, is subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

Story continues

More here:
Hemostemix Files Its Audited Annual Financial Statements and Management Discussion and Analysis for the Period Ending December 31, 2019 - Yahoo...

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Professional Survey Report 2026: By Product, Application, Manufacturer, Sales and…

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Marketplace gives detailed Evaluation about all of the Important aspects regarding the marketplace. The analysis on Global Autologous Stem Cell and Non-Stem Cell Based Therapies economy, offers profound insights regarding the Autologous Stem Cell and Non-Stem Cell Based Therapies marketplace covering all of the significant characteristics of the marketplace. In addition, the report offers historical information with prospective prediction over the forecast period. Various critical aspects like market trends, earnings development patterns market stocks and supply and demand are contained in practically all of the market research document for every single business. A number of the vital facets analysed in the report contains market share, creation, key areas, earnings rate in addition to key players.

The analysis of different sections of the Global Autologous Stem Cell and Non-Stem Cell Based Therapies market are also Covered in the study report. Along with this, for the prediction periods conclusion of variables such as market size and the competitive landscape of this sector is assessed in the report. On account of the rising globalization and digitization, there are new tendencies coming to the marketplace daily. The study report provides the detailed analysis of all of these tendencies.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2632388&source=atm

Additionally, the Autologous Stem Cell and Non-Stem Cell Based Therapies marketplace report also supplies the Latest tendencies in the Global Autologous Stem Cell and Non-Stem Cell Based Therapies marketplace with the assistance of primary in addition to secondary research methods. Also, the analysis report on Autologous Stem Cell and Non-Stem Cell Based Therapies marketplace gives a wide evaluation of the marketplace including market review, manufacturing, manufacturers, dimensions, cost, value, growth rate, earnings, prices, export, consumption, and sales revenue of this Global Autologous Stem Cell and Non-Stem Cell Based Therapies market. On the flip side, the Autologous Stem Cell and Non-Stem Cell Based Therapies marketplace report also studies the industry standing for the prediction period. Nevertheless, this can help to grow the advertising opportunities throughout the world in addition to major market suppliers.

The key players covered in this study Fibrocell Science, Inc. Vericel Corporation Dendreon Corporation (Sanpower Group) Caladrius Biosciences, Inc. BrainStorm Cell Therapeutics Regeneus Ltd. Genzyme Corporation Pluristem Therapeutics Inc U.S. Stem Cell, Inc TiGenix (Takeda)

Market segment by Type, the product can be split into Autologous Stem Cell Therapy Non-Stem Cell Therapy Market segment by Application, split into Cancer Neurodegenerative Disorders Cardiovascular Disease Autoimmune Diseases Others

Market segment by Regions/Countries, this report covers North America Europe China Japan Mid East & Africa Australia

The study objectives of this report are: To analyze global Autologous Stem Cell and Non-Stem Cell Based Therapies status, future forecast, growth opportunity, key market and key players. To present the Autologous Stem Cell and Non-Stem Cell Based Therapies development in North America, Europe, China, Japan, Mid East & Africa and Australia. To strategically profile the key players and comprehensively analyze their development plan and strategies. To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Autologous Stem Cell and Non-Stem Cell Based Therapies are as follows: History Year: 2015-2019 Base Year: 2019 Estimated Year: 2020 Forecast Year 2020 to 2026 For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2632388&source=atm

The Autologous Stem Cell and Non-Stem Cell Based Therapies market report provides useful insights for Every established and advanced players throughout the world. Additionally the Autologous Stem Cell and Non-Stem Cell Based Therapies marketplace report provides accurate evaluation for the changing competitive dynamics. This study report includes a whole analysis of future expansion concerning the evaluation of this mentioned prediction interval. The Autologous Stem Cell and Non-Stem Cell Based Therapies marketplace report provides a thorough analysis of the technological advancement prognosis over time to be aware of the industry growth prices. The Autologous Stem Cell and Non-Stem Cell Based Therapies marketplace report also has innovative analysis of the massive number of unique facets which are fostering or functioning in addition to regulating the Autologous Stem Cell and Non-Stem Cell Based Therapies marketplace development.

A systematized methodology can be utilized to create a Study on the Global Autologous Stem Cell and Non-Stem Cell Based Therapies Sector. For the research of economy on the Conditions of study Approaches, these strategies are useful. All of the Information Regarding this Products, makers, vendors, clients and even more is covered in research reports. Various important factors like market trends, earnings Growth patterns market stocks and supply and demand are contained in virtually all The market study report for every single business. Adaptation of fresh thoughts and Accepting the most recent tendencies are a few the causes of virtually any markets growth. The Global Autologous Stem Cell and Non-Stem Cell Based Therapies market research report provides the profound understanding concerning the Areas in which the marketplace is impactful.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2632388&licType=S&source=atm

View post:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Professional Survey Report 2026: By Product, Application, Manufacturer, Sales and...

Orchard Therapeutics, MolMed Extend Gene Therapy Mfg. Pact – Contract Pharma

MolMed to support the development and manufacture of vectors and drug products for Orchards investigational hematopoietic stem cell (HSC) gene therapies.

Contract Pharma Staff07.09.20

Orchard Therapeutics and MolMed S.p.A have extended their collaboration initiated in April 2018, through June 2025. MolMed will continue to support activities related to the development and manufacture of vectors and drug products for several of Orchards investigational ex vivo hematopoietic stem cell (HSC) gene therapies, including OTL-200 for metachromatic leukodystrophy (MLD), OTL-103 for Wiskott Aldrich syndrome (WAS), and OTL-203 for mucopolysaccharidosis type I (MPS-I).

MolMed is the first company to have obtained good manufacturing practice (GMP) authorization for the gene and cell therapy markets in Europe and is the manufacturer for Strimvelis, Orchards ex vivo HSC gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) and the first such treatment approved by the European Medicines Agency (EMA).

OTL-200 for MLD is currently under review by the EMA with a decision expected later this year.

See original here:
Orchard Therapeutics, MolMed Extend Gene Therapy Mfg. Pact - Contract Pharma

Brazilian HIV patient cured: Can this be true? – Deutsche Welle

The Sao Paulo patient is a 36-year-old man who finished an antiretroviral therapy treatment to specifically address HIV/AIDS in March 2019. The news raises myriad questions in the scientific community. Additionally, the data are preliminary and the case is particularly compelling because, of the five people who received the treatment, only one has been cured.

Jrgen Rockstroh, professor and doctor of medicine and the head of the outpatient Clinic for Infectious Diseases and Immunology at the Center for Integrated Oncology at the University Clinic in Bonn, said: "These are exciting findings, but they're very preliminary. This has happened to one person, and one person only, but it did not succeed in four others given the same treatment. Clearly, reproducibility of the findings or confirmation in an additional individual would be important."

If the case were proven, it would be a monumental discovery. However, Brazilian scientists say the results are yet to be confirmed, and testing is ongoing.

Why is it so difficult to cure HIV?

HIV inserts its genetic material into the DNA of its target immune cell obliging the cell to form copies of the virus. In this way, the HIV integrates itself directly into the DNA and literally becomes part of its host's body. This makes the virus incredibly difficult to treat.

HIV hides in those cells residing dormant in them for years before it wakes up and causes acquired immunodeficiency syndrome (AIDS). Some scientists believe that the dormant stage is an evolutionary advantage to the virus. In the sites where HIV first enters the body, there are few immune cells to infect.

If the virus destroys all these few existing cells immediately after invasion, there will be no immune cells left to carry the infection to further cells. Rather, the HIV delays its activation until it is carried by those cells initially infected to tissues where it can infect even more cells.

This process ensures a better chance for the virus to spread. This dormant or latent stage can last up to 12 years. After the virus wakes up, the immune system weakens, and AIDS develops. A weakened immune system leaves the patient prone to mild infections that an otherwise healthy individual would likely not develop.

Only two people have been completely cured from HIV

Two patients in London and Berlin underwent a risky bone marrow transplant from a very particular donor, who was discovered to have a natural immunity to HIV. The bone marrow from this individual is immune to the virus due to a mutation in one of the receptors of the immune cells that HIV must be able to enter to successfully cause AIDs.

Before the stem-cell transplantation, doctors destroyed the immune cells carrying the HIV virus in their DNA from the Berlin patient's bone marrow. Later, the naturally mutated stem-cells from the donor were transplanted. The procedure is precarious and can result in life threating conditions, such as graft-versus-host disease, where the body rejects the transplant.

While long-term remission was achieved in these two patients, a bone marrow transplant is not a viable cure for all cases. These patients underwent this experimental treatment to address cancer diagnoses.

How is HIV treated?

Antiretrovirals hinder viral replication, as well as attachment to target cells. The purpose is to stop any viral activity and viral production. Currently, antiretroviral therapy can decrease the viral load in the body to an extent that the person is no longer infectious.

Read more:Stem cell transplants and HIV: What you need to know

If the viral load remains undetectable, one could have unprotected sex without infecting their partner. Moreover, HIV would not be transmitted from a mother to a child in this case. However, if the antiretroviral therapy is stopped, the control of virus replication ends.

The So Paulo patient received antiretrovirals. When asked whether it is possible to expect a complete elimination of a virus which integrates itself in the DNA by antiretroviral drugs, Dr. Rockstroh said, "numerous studies including intensified 3-drug therapy (including maraviroc and dolutegravir given to the Brazilian patient) even very early in HIV-infection were not able to achieve viral elimination or even decrease reservoir over time in multiple clinical trials."

Dr. Rockstroh explained that patients taking post-treatment controllers showed no signs of restarted viral replication for over one year after interrupting anti-retroviral therapy. However, the complete elimination of the virus has not been found in these patients.

How does the immune system react?

The physician added, "As each individual immune system reacts very differently and the spectrum of immune response ranges from rapid disease progression to elite controllers who have no signs of ongoing replication in plasma over years without treatment makes single cases very difficult to generalize from."

The So Paulo patient received a cocktail of antiretroviral drugs, including nicotinamide, a form of vitamin B3, which is thought to wake up the hidden virus and lure it out of its reservoirs. This is done to highlight infected cells for other drugs, so the immune system can kill the virus.

Dr. Rockstroh suggested the approach of virus activation could be significant in finding a functional cure for HIV. Whether this approach works or contributes to this specific case is still unknown.

Scientists are questioning the case and raising the concerns that the patient may have continued to take antiretroviral drugs without the knowledge of the study team. The team commented that they plan to check his blood for antiviral drugs to rule out this possibility.

What is also intriguing about the case is the loss of HIV antibodies. Dr. Rockstroh suggested that the weakening of the antibody test overtime is due to a diminishing immune response. However, the reasons for this remain unclear and require further testing.

Former South African president Thabo Mbeki (1999 - 2008) went down in history as the foremost African denier of AIDS. Against all scientific evidence he maintained that HIV did not cause AIDS. He instructed his health officials to combat the disease with herbal remedies. Experts believe his denialism cost up to 300,000 lives. Some have called for Mbeki to be tried for crimes against humanity.

In 2007 former Gambian president Yahya Jammeh (1996 - 2017) forced AIDS patients to undergo a cure that he had personally developed. It turned out to be a concoction based on herbs; an unknown number of people died. Jammeh, who claimed that he had mystic powers, is the first African head of state to be tried for violating the rights of HIV-positive people.

Another former South African head of state to make headlines for an unconventional take on AIDS was Jacob Zuma (2009 - 2018). After being charged with raping an HIV-positive woman in 2006, Zuma said he was not at risk of infection, despite not using a condom, because he had "taken a shower afterwards." In 2010 he disclosed the negative results of his AIDS test, to fight the stigma, he said.

Ugandas President Yoweri Museveni took his time before joining the fight against the epidemic. As late as 2004, during an international AIDS conference in Thailand, he downplayed the effectiveness of condoms, alleging, among other things, that they ran counter to some African sexual practices. "We dont think we can become universally condomised," he said. His remarks were met with laughter.

Some action taken by African heads of state to fight the scourge did not go down well at home. A tax introduced in 1999 by Zimbabwe's President Robert Mugabe (1987-2017) to help orphans and sufferers met with resistance. It is still in place today. In 2004 Mugabe admitted that his own family had been affected by AIDS. He said the disease was "one of the greatest challenges facing our nation."

Fear of economic repercussions affecting, for example, tourism, is one reason why African leaders have been reluctant to acknowledge the threat. But President Kenneth Kaunda of Zambia (1964-1991) announced as early as 1987 that one of his sons had died of AIDS. In 2002 he was the first African leader to take an AIDS test. He still fights against AIDS today.

The fight against AIDS by Kaundas successor Edgar Lungu met with some hitches when he tried to make AIDS-testing compulsory in Zambia. Lungu said in 2016 that the policy was non-negotiable. But a huge outcry in Zambia and abroad forced him to backpedal especially as the World Health Organization made clear that compulsion encourages the stigmatization of HIV-positive people.

After leaving office, Festus Mogae, former president of Botswana (1998-2008), launched Champions for an AIDS-Free Generation, which brings together a number of former African presidents and other influential personalities eager to help fight the scourge. They hope that their experience and influence will enable them to exert pressure on governments and partners to invest in AIDS prevention.

Author: Cristina Krippahl

Here is the original post:
Brazilian HIV patient cured: Can this be true? - Deutsche Welle